CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 101 enrolled
Drug / intervention
Bortezomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02703779
NCT02703779Phase 2Completed
CompareCT.gov

An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma

Siddhartha Ganguly·interventional·Posted Mar 9, 2016·Updated Jun 18, 2021

In Brief

A Phase 2 clinical trial evaluating Bortezomib, Granulocyte colony-stimulating factor (G-CSF), and 1 other intervention for Multiple Myeloma. Completed, enrolled 101 participants across 1 site.

Detailed Summary

Explore stem cell collection with or without bortezomib with in-vivo purging in multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 9, 2016
Enrollment StartMar 1, 2016
Primary CompletionOct 4, 2019
Study CompletionApr 8, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 10.3 years ago

Interventions

Bortezomibdrug

Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.

Granulocyte colony-stimulating factor (G-CSF)drug

Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.

Mozobildrug

Mozobil will be given to all participants by injection under the skin only if needed per Investigator.